The impact of N-nitrosamine impurities on clinical drug development

Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product N-Nitrosamine Impurities

(2022) Krista L. Dobo et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Rifampin drug‐drug‐interaction studies; reflections on the nitrosamine impurities issue

(2022) Aernout van Haarst et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A literature review of liver function test elevations in rifampin drug–drug interaction studies

(2022) Sherry M. Ibrahim et al.   CTS-Clinical and Translational Science

Metabolic Activation and DNA Interactions of Carcinogenic N-Nitrosamines to Which Humans Are Commonly Exposed

(2022) Yupeng Li et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug–drug interaction studies

(2022) Jayaprakasam Bolleddula et al.   CTS-Clinical and Translational Science

PBPK perspective on alternative CYP3A4 inducers for rifampin

(2022) Kuan‐Fu Chen et al.   CPT-Pharmacometrics & Systems Pharmacology

The Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals

(2022) Joerg Schlingemann et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Permitted daily exposure limits for noteworthy N‐nitrosamines

(2021) George E. Johnson et al.   ENVIRONMENTAL AND MOLECULAR MUTAGENESIS

The nitrosamine contamination of drugs, part 3: Quantification of 4-Methyl-1-nitrosopiperazine in rifampicin capsules by LC-MS/HRMS

(2021) Jonas Wohlfart et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

A genome-wide portrait of pervasive drug contaminants

(2021) Joseph Uche Ogbede et al.   Scientific Reports

Estimated Cancer Risks Associated with Nitrosamine Contamination in Commonly Used Medications

(2021) Kate Li et al.   International Journal of Environmental Research and Public Health

Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data

(2020) Andrew Thresher et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Critical review of major sources of human exposure to N -nitrosamines

(2018) Adam J. Gushgari et al.   CHEMOSPHERE

Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study

(2018) Anton Pottegård et al.   BMJ-British Medical Journal

Dietary exposure to volatile and non-volatile N-nitrosamines from processed meat products in Denmark

(2015) S.S. Herrmann et al.   FOOD AND CHEMICAL TOXICOLOGY

Impact of Efavirenz on Intestinal Metabolism and Transport: Insights From an Interaction Study With Ezetimibe in Healthy Volunteers

(2012) S Oswald et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Mechanism of Efavirenz Influence on Methadone Pharmacokinetics and Pharmacodynamics

(2012) E D Kharasch et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Enzyme induction with antiepileptic drugs: Cause for concern?

(2012) Martin J. Brodie et al.   EPILEPSIA

Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers

(2010) L. Vlase et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Carbamazepine,HLA-B*1502and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations

(2008) P Brent Ferrell et al.   PHARMACOGENOMICS